^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Mylotarg (gemtuzumab ozogamicin) (DNA replication inhibitor, CD33-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Nat Commun
    Title:

    Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios

    Published date:
    06/27/2022
    Excerpt:
    CONTRADICTING EVIDENCE: Here, we present the outcome and prognostic significance of FLT3/ITD AR analysis among pediatric patients with AML from the TARGET dataset....our subgroup analysis demonstrated that the high AR FLT3/ITD patients who received consolidation chemotherapy plus GO (n = 21), had an inferior 5-year EFS (16.7% (37%) vs. 57.1% (55.1%), P = 0.023; Fig. 6C) and OS (25.6% (39.7%) vs. 71.4% (46.6%), P = 0.014; Fig. 6D) compared to those with SCT plus GO (n = 14).
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1038/s41467-022-31489-9
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2020
    Title:

    ADDITION OF ANTI-CD33 MONOCLONAL ANTIBODY GEMTUZUMAB OZOGAMICIN TO FLAI INDUCTION SIGNIFICANTLY IMPROVES OUTCOME IN PATIENT AFFECTED BY FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA

    Published date:
    05/14/2020
    Excerpt:
    This effect was more evident among the 33 NPM1wt/FLT3-ITD patients: in this subgroup, patients who received GO had an overall good outcome, similar to those double mutated (median OS not reached in both groups, p=n.s.)...our data seem to indicate that  GO added to an intensive fludarabine/high dose ARA-C  based induction, provides a significant improvement of anti-leukemic activity in patients carrying FLT3-ITD mutation, especially if NPM1wt.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Addition of the Anti-CD33 Monoclonal Antibody Mylotarg to Fludarabine/High Dose Cytarabine - Based Induction Significantly Improves Outcome in Patient Affected By FLT3-ITD Positive Cytogenetically Normal Acute Myeloid Leukemia

    Published date:
    11/06/2019
    Excerpt:
    ...a significant positive effect on survival among FLT3-ITD patients (3-year OS 66.7% vs 46.6% for FLT3-ITD patients receiving or not MY, respectively, p<0.03, Fig. 1). This effect was more evident among the 33 NPM1 negative/FLT3-ITD patients: in this subgroup, patients who received MY had an overall good outcome
    DOI:
    10.1182/blood-2019-131420